Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient

doi:10.1111/1753-0407.12956

	Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient
	Li, Wen 2,3; Liu, Ruixin 2,3; Li, Xuelin 2,3; Tao, Bei 2,3; Zhai, Nan 2,3; Wang, Xiaolin 4; Li, Qi 4; Zhang, Yifei 2,3; Gu, Weiqiong 2,3; Wang, Weiqing 2,3
刊名	JOURNAL OF DIABETES
	2019-07-29
页码	11
关键词	bile acids dipeptidyl peptidase-4 inhibitor obesity saxagliptin type 2 diabetes
ISSN号	1753-0393
DOI	10.1111/1753-0407.12956
通讯作者	Wang, Weiqing(wqingw61@163.com)
英文摘要	Background The aim of the present study was to investigate the metabolic benefits of saxagliptin and its effects on serum bile acids (BAs) in normal weight and overweight/obese drug-naive type 2 diabetes (T2D) patients. Methods In all, 282 drug-naive T2D patients (123 normal weight [NW], with body mass index [BMI] between 19.0 and <25.0 kg/m(2); 159 overweight/obese [OW/OB], with BMI >= 25.0 kg/m(2)) were enrolled in the study and treated with saxagliptin 5 mg daily for 24 weeks. Serum BAs were assayed by liquid chromatography with tandem mass spectrometry. Results At 24 weeks, HbA1c was significantly reduced in both groups, but the HbA1c levels were lower in the OW/OB than NW group. Moreover, significant decreases were seen at 24 weeks in C-reactive protein (CRP), aspartate aminotransferase, alanine aminotransferase, waist circumference, and systolic blood pressure in the OW/OB group. Interestingly, cholic acid, glycocholic acid, glycochenodeoxycholic acid, glycodeoxycholic acid (GDCA), and glycoursodeoxycholic acid (GUDCA) were increased in both groups after treatment, whereas chenodeoxycholic acid and deoxycholic acid (DCA) were specifically increased in the OW/OB group. Increased DCA and GDCA concentrations were significantly associated with decreased HbA1c or fasting blood glucose and CRP levels, whereas increased GDCA and GUDCA concentrations were associated with decreased waist circumference in the OW/OB group during treatment. In the NW group, increased GUDCA concentrations were significantly associated with a decrease in HbA1c. Conclusions Type 2 diabetes patients with OW/OB exhibited greater improvement in glycemic control and additional metabolic benefits after saxagliptin treatment. Saxagliptin significantly increased the BA pool, and DCA and GDCA were associated with metabolic improvements in OW/OB T2D patients.
资助项目	National Key R&D Program of China[2018YFC1314800] ; Chinese National Natural Science Foundation[81730023] ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support[20161403]
WOS关键词	DIPEPTIDYL PEPTIDASE-4 INHIBITORS ; Y GASTRIC BYPASS ; INSULIN-RESISTANCE ; GUT MICROBIOME ; FATTY LIVER ; WEIGHT-LOSS ; RECEPTOR ; METFORMIN ; IDENTIFICATION ; INFLAMMATION
WOS研究方向	Endocrinology & Metabolism
语种	英语
出版者	WILEY
WOS记录号	WOS:000481367900001
资助机构	National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; National Key R&D Program of China ; National Key R&D Program of China ; Chinese National Natural Science Foundation ; Chinese National Natural Science Foundation ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support ; Shanghai Municipal Education Commission - Gaofeng Clinical Medicine Grant Support
内容类型	期刊论文
源URL	[http://cas-ir.dicp.ac.cn/handle/321008/173557]
专题	大连化学物理研究所_中国科学院大连化学物理研究所
通讯作者	Wang, Weiqing
作者单位	1.Chinese Acad Sci, Lab Endocrinol & Metab, Inst Hlth Sci, Shanghai Inst Biol Sci, Shanghai, Peoples R China 2.Shanghai Jiao Tong Univ, Dept Endocrine & Metab Dis,Ruijin Hosp, Shanghai Key Lab Endocrine Tumours,Shanghai Clin, Shanghai Inst Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China 3.Shanghai Inst Endocrinol, Shanghai, Peoples R China 4.Chinese Acad Sci, Key Lab Separat Sci Analyt Chem, Dalian Inst Chem Phys, Dalian, Peoples R China 5.Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Li, Wen,Liu, Ruixin,Li, Xuelin,et al. Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient[J]. JOURNAL OF DIABETES,2019:11.
APA	Li, Wen.,Liu, Ruixin.,Li, Xuelin.,Tao, Bei.,Zhai, Nan.,...&Ning, Guang.(2019).Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient.JOURNAL OF DIABETES,11.
MLA	Li, Wen,et al."Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naive overweight or obese type 2 diabetes patient".JOURNAL OF DIABETES (2019):11.